Marc co-founded Minoryx in 2011 and since then has been taken the CEO role. He obtained a PhD in Chemistry from the University of Barcelona and has 15+ years of experience in drug discovery and development. Prior founding Minoryx, he worked at Crystax Pharmaceuticals and Oryzon Genomics where he managed several research projects and led the team in charge of target selection, structural biology, computational chemistry and hit ID through a fragment-based approach. At Oryzon, Marc actively contributed to the identification of the first-in-class inhibitors for the epigenetic target LSD1 currently in clinical studies. Marc always had an entrepreneurial calling.
